Cargando…
A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
BACKGROUND: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. MATERIAL AND METHODS: This 5-year retrosp...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medicina Oral S.L.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432112/ https://www.ncbi.nlm.nih.gov/pubmed/28390132 http://dx.doi.org/10.4317/medoral.21728 |
_version_ | 1783236573917085696 |
---|---|
author | Manfredi, Maddalena Mergoni, Giovanni Goldoni, Matteo Salvagni, Stefania Merigo, Elisabetta Meleti, Marco Vescovi, Paolo |
author_facet | Manfredi, Maddalena Mergoni, Giovanni Goldoni, Matteo Salvagni, Stefania Merigo, Elisabetta Meleti, Marco Vescovi, Paolo |
author_sort | Manfredi, Maddalena |
collection | PubMed |
description | BACKGROUND: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. MATERIAL AND METHODS: This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. RESULTS: Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program after the beginning of ZA therapy (P=0.02) were the only factors which showed a significant association with the occurrence of ONJ. CONCLUSIONS: This study demonstrated the importance of beginning dental prevention before zoledronic acid exposure in reducing ONJ occurrence, especially in the long term. The results of this research show that control of periodontal disease and an increase in the time between tooth extraction and the first ZA administration are recommended in order to reduce the risk of ONJ development. Key words:Osteonecrosis of the jaw, dental prevention, zoledronic acid, incidence. |
format | Online Article Text |
id | pubmed-5432112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medicina Oral S.L. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54321122017-05-18 A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors Manfredi, Maddalena Mergoni, Giovanni Goldoni, Matteo Salvagni, Stefania Merigo, Elisabetta Meleti, Marco Vescovi, Paolo Med Oral Patol Oral Cir Bucal Research BACKGROUND: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. MATERIAL AND METHODS: This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. RESULTS: Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program after the beginning of ZA therapy (P=0.02) were the only factors which showed a significant association with the occurrence of ONJ. CONCLUSIONS: This study demonstrated the importance of beginning dental prevention before zoledronic acid exposure in reducing ONJ occurrence, especially in the long term. The results of this research show that control of periodontal disease and an increase in the time between tooth extraction and the first ZA administration are recommended in order to reduce the risk of ONJ development. Key words:Osteonecrosis of the jaw, dental prevention, zoledronic acid, incidence. Medicina Oral S.L. 2017-05 2017-04-08 /pmc/articles/PMC5432112/ /pubmed/28390132 http://dx.doi.org/10.4317/medoral.21728 Text en Copyright: © 2017 Medicina Oral S.L. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Manfredi, Maddalena Mergoni, Giovanni Goldoni, Matteo Salvagni, Stefania Merigo, Elisabetta Meleti, Marco Vescovi, Paolo A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors |
title | A 5-year retrospective longitudinal study on the incidence and the risk
factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone
metastases from solid tumors |
title_full | A 5-year retrospective longitudinal study on the incidence and the risk
factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone
metastases from solid tumors |
title_fullStr | A 5-year retrospective longitudinal study on the incidence and the risk
factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone
metastases from solid tumors |
title_full_unstemmed | A 5-year retrospective longitudinal study on the incidence and the risk
factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone
metastases from solid tumors |
title_short | A 5-year retrospective longitudinal study on the incidence and the risk
factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone
metastases from solid tumors |
title_sort | 5-year retrospective longitudinal study on the incidence and the risk
factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone
metastases from solid tumors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432112/ https://www.ncbi.nlm.nih.gov/pubmed/28390132 http://dx.doi.org/10.4317/medoral.21728 |
work_keys_str_mv | AT manfredimaddalena a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT mergonigiovanni a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT goldonimatteo a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT salvagnistefania a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT merigoelisabetta a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT meletimarco a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT vescovipaolo a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT manfredimaddalena 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT mergonigiovanni 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT goldonimatteo 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT salvagnistefania 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT merigoelisabetta 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT meletimarco 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors AT vescovipaolo 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors |